| Name | Title | Contact Details |
|---|
Dare to bank boldly and dream big. Whatever your dreams, its time to take your financial future to new heights. Were committed to helping you get there. Embold Credit Union is a local, member-owned, not-for-profit financial cooperative. That means when you join Embold, you become a member and an owner. All decisions we make keep your best interests at the forefront.
ACTS is a 35-year-old nonprofit based in the Commonwealth of Virginia (U.S.A.) that is supported by all of the worlds leading light car and truck makers. Our mission is to research, educate and promote highway and motor vehicle safety.
HBK CPAs & Consultants is a multidisciplinary financial services firm based in Canfield, Ohio, with operations in several states, including Pennsylvania, New Jersey, New York, and Florida. Established in 1949, HBK is one of the largest accounting firms in the U.S., ranking 46th in recent listings. The firm is dedicated to collaboration and a holistic approach to client service, emphasizing integrity, respect, and transparency. HBK offers a comprehensive range of financial services tailored for small to mid-market businesses. Their offerings include accounting and audit services, tax planning and compliance, wealth management through HBKS Wealth Advisors, business valuation, corporate finance, forensic accounting, and business consulting. With a client base of over 20,000, HBK provides customized solutions to meet the unique financial needs of its clients. The firm has also received recognition from notable publications for its excellence in wealth management services.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Dedicated to assisting organizations leverage value from their most significant and least understood asset - their data.